For healthcare professionals

Evaluating Ozzi for a patient on medication

Your patient may have handed you this page. It covers what's in each stick, why each ingredient is there, and the medication considerations worth checking before you decide.

Please read first

This page was compiled with the help of AI and has not been reviewed by a licensed physician or pharmacist. It is provided as reference material for a healthcare professional's own evaluation. Please verify anything that matters for your patient against your usual clinical references, and use your professional judgement.

What it is

A flavored drink stick mixed into water. A dietary supplement, not a drug, and not evaluated by the FDA for any indication.

How it's taken

After a meal, as a snack replacement. Most people take 1 stick after dinner, when evening cravings hit. Up to 2 sticks daily, each after a meal. Ozzi is not a pre-meal drink.

Contains

6 active ingredients, detailed below. No caffeine, no stimulants, no berberine, no artificial sweeteners.

Check first

Glucose-lowering drugs, levothyroxine, and oral drugs with a narrow therapeutic range. The medication table below explains why.

GLP-1 RA patients

Commonly used alongside therapy for evening cravings. The fiber is deliberately dosed low for GI tolerability. See the dedicated section.

Not

Not a substitute for any prescribed therapy, and not a taper aid for GLP-1 receptor agonists.

What's in it, and why

6 actives, each with a job in the blend

Each card gives the amount, the reason it's in Ozzi, its purported role, and how strong the evidence is. Where an ingredient matters for medication use, that's called out at the bottom of the card.

Alluloseas allSWEET. A rare sugar

8 g16 g at 2 sticks
Why it's in Ozzi

It gives an evening snacker something genuinely sweet without the sugar. It's the main thing that makes Ozzi work as a snack replacement.

Purported role

Satisfies sweet cravings without the blood sugar spike. Allulose is minimally metabolized, contributes negligible calories, and doesn't raise blood glucose or insulin the way sucrose does. It also supports healthy post-meal blood sugar already within the normal range, and stimulates GLP-1 release in animal studies.

Evidence

Strong as a non-glycemic sweetener. Moderate for post-meal glucose, where the effect is clearest in type 2 diabetes.

Medication noteMay add to the effect of glucose-lowering therapy. GI symptoms are more likely at 2 sticks.

L-Lysine Butyrateas BIOMEnd. A postbiotic short-chain fatty acid

500 mg1 g at 2 sticks
Why it's in Ozzi

Butyrate is what gut bacteria make from fiber, and it's the fuel the colon lining runs on. We use the lysine-bound form because it's absorbed quickly, carries no sodium, and was the most palatable form in human testing.

Purported role

Supports the gut lining and a healthy gut barrier. Also supports natural GLP-1 production by stimulating the L-cells that secrete GLP-1 and PYY, shown in cell and animal models with human confirmation still pending.

Evidence

Strong for gut lining and barrier support. Preclinical for GLP-1. Human pharmacokinetic data shows peak serum butyrate at 20 minutes.

Medication noteNo well-characterized drug interactions. Butyrate is an HDAC inhibitor, so for a patient on HDAC-inhibitor oncology therapy, check with the treating oncologist.

Konjac GlucomannanViscous soluble fiber from konjac root

500 mg1 g at 2 sticks
Why it's in Ozzi

It adds physical fullness after a meal. We dose it well below the 3 g per day used in weight management protocols on purpose, because a viscous fiber at that level slows digestion further in patients whose gastric emptying is already delayed, such as those on GLP-1 receptor agonists.

Purported role

Helps you feel full. Glucomannan absorbs water and forms a gel, adding bulk and slowing carbohydrate absorption.

Evidence

Moderate The mechanism is well established. The full satiety effect in the literature is at higher doses than ours, which is a trade we made for tolerability.

Medication noteThe ingredient most likely to matter. Viscous fiber can reduce or delay absorption of oral drugs taken at the same time. See the table below.

Chromiumas Metabolex chromium polyursolate

300 mcgelemental. 600 mcg at 2 sticks
Why it's in Ozzi

Chromium is an essential trace mineral involved in insulin signaling. We use it bound to ursolic acid, which delivers both in one ingredient.

Purported role

Supports healthy blood sugar already within the normal range by supporting how cells respond to insulin. 300 mcg is 857% of the 35 mcg Daily Value and sits within the 200 to 1,000 mcg range commonly studied.

Evidence

Moderate Well studied, with effects seen mostly in people with impaired glucose regulation rather than in healthy adults.

Medication noteRelevant with insulin and sulfonylureas, and with levothyroxine, whose absorption chromium can reduce. Use caution in renal or hepatic impairment.

Ursolic AcidDelivered within the Metabolex complex

In the 11 mgcomplex, with chromium
Why it's in Ozzi

It's what chromium is bound to in Metabolex, and it brings metabolic activity of its own rather than acting as a passive carrier.

Purported role

Supports metabolic signaling through AMPK, the cell's energy sensor, and has been studied for effects on inflammatory signaling pathways in cell and animal models. The ingredient manufacturer reports early data suggesting ursolic acid may be roughly 5 to 10 times more bioavailable in Metabolex form than as standard ursolic acid.

Evidence

Emerging Mechanistic and animal data. The bioavailability figure is the manufacturer's early data, and we can share the source on request.

Medication noteLimited interaction data. AMPK activation overlaps in mechanism with metformin, so treat the combination as worth watching rather than as a known interaction.

African MangoIrvingia gabonensis seed extract

150 mg300 mg at 2 sticks
Why it's in Ozzi

It supports the appetite side of the formula, and at 2 sticks it reaches the 300 mg daily amount used in its best-known human trial.

Purported role

Supports appetite hormones, including leptin, the hormone that signals fullness, alongside healthy metabolic markers.

Evidence

Limited Human trial data exists, but largely from one research group. That study also gave it before meals, and Ozzi is taken after.

Medication noteLimited interaction data. Theoretically additive with glucose-lowering and lipid-lowering therapy.

Inactive ingredients: citric acid, silica, natural flavor, L-tartaric acid, Reb M, pink Himalayan salt, trisodium citrate. Vegan. Doses are rounded down from the production specification.

Medication considerations

What to check, by drug class

Considerations are flagged by how much they're likely to matter, and theoretical ones are labeled as theoretical. This list isn't exhaustive, and it isn't a substitute for your own interaction check.

Medication considerations for Ozzi

Ordered by how likely each is to matter in practice

Drug classLevelIngredientWhat to consider
Insulin and sulfonylureasMonitorChromium, allulose, glucomannanThree ingredients act on glucose through different routes. The combined effect is modest, but for a patient on hypoglycemia-prone therapy, monitor glucose when starting rather than assuming Ozzi is inert.
LevothyroxineSeparateGlucomannan, chromiumBoth fiber and chromium can reduce levothyroxine absorption. Levothyroxine is usually taken fasting in the morning and Ozzi after meals, so usual timing already keeps them apart. Worth confirming with the patient.
Oral drugs with a narrow therapeutic rangeSeparateGlucomannanExamples include warfarin, digoxin, lithium and antiepileptics. Viscous fiber can delay or reduce absorption of oral drugs taken at the same time. General guidance for soluble fiber is to take oral medications at least 1 hour before, or a few hours after.
Injectable GLP-1 receptor agonistsConsiderGlucomannan, alluloseNo known pharmacological interaction. These patients often have delayed gastric emptying and GI side effects, and fiber plus allulose may add to nausea or bloating. Starting at 1 stick after dinner is sensible.
Oral GLP-1 receptor agonist tabletsTimingAllThese tablets have strict fasting administration requirements before any food, drink or other medication. Ozzi taken after a later meal doesn't conflict, but it shouldn't be taken in that pre-dose window.
MetforminTheoreticalUrsolic acid, chromiumUrsolic acid acts through AMPK, as metformin does, and chromium supports insulin response. No interaction is documented. Mentioned because the mechanisms overlap.
HDAC-inhibitor oncology therapyTheoreticalButyrateButyrate is itself an HDAC inhibitor. No interaction is documented at supplement doses, but defer to the treating oncologist.
Everything elseLowNo caffeine or stimulants, so no concern with blood pressure or cardiac medications on that front. No berberine, which is common in this category and carries real CYP interaction potential.

Populations

Pregnancy and lactationNot studied. We don't recommend use.
Renal impairmentNot studied. Use caution given the chromium content.
Hepatic impairmentNot studied. Use caution.
Dysphagia, strictures, GI obstructionGlucomannan expands in water. Ozzi must be fully dissolved in a full glass of liquid, and isn't appropriate for these patients without your input.
ChildrenNot intended for anyone under 18.

Alongside GLP-1 receptor agonist therapy

Why patients on therapy use it, and what it does and doesn't do for them

Many patients on GLP-1 receptor agonists still describe evening cravings, and that's what they tell us they use Ozzi for. For these patients the value is in the non-hormonal part of the blend: something sweet after dinner without the sugar, butyrate supporting the gut lining, and a small amount of fiber for fullness.

We don't claim Ozzi adds to the GLP-1 effect of their medication. Butyrate's L-cell activity is preclinical, and no study has tested Ozzi alongside GLP-1 receptor agonist therapy. The glucomannan dose was set low specifically so it doesn't compound the slowed digestion these patients already have.

What customers on GLP-1 receptor agonist therapy told us

12 of 66 survey respondents. Self-selected, self-reported, no control group

Said Ozzi is working12 of 12
12
100%
Food noise "gone way down"5 of 12, vs 18% of others
5
42%

12 current customers who chose to answer a survey with a coupon offered for completion. Customers who tried Ozzi on therapy and stopped aren't represented.

"The food noise is much less and because I feel full, when I eat, I eat less. If I get hungry between meals, I grab a stick, mix in water, and the temptation to eat is gone."

Customer report / Marty M., 60+ / on GLP-1 RA therapy

"It has provided me with something sweet to quiet my sweet tooth while also impacting fullness cues. I almost use it as a meditation now."

Customer report / Deborah R., 50-59 / on GLP-1 RA therapy

Patients asking about coming off therapy

Ozzi isn't a taper aid and we don't position it as one. Only 1 of our 66 survey respondents had stopped a GLP-1 receptor agonist, and that person hadn't noticed a benefit. We have no data on weight maintenance or glycemic control after discontinuation. Those decisions sit with you and your patient.

Customer-reported outcomes

What 66 customers told us

From our 2026 customer survey. Self-reported, current customers only, no control group, so treat these as a best case rather than an average.

n = 66. Share reporting any improvement; the darker segment is a strong change

Snacking less
33%
61%
94%
Feeling full sooner
24%
59%
17%
83%
Food noise down
23%
61%
17%
83%
Sugar cravings down
17%
62%
21%
79%

12% of respondents noticed no benefit. 49 of 66 took 1 stick a day.

How this page was made. This reference was compiled with the help of AI from Ozzi's ingredient specifications, internal substantiation notes and customer survey. It has not been reviewed by a licensed physician, pharmacist or other medical professional. It is intended for evaluation by healthcare professionals, who should rely on their own clinical references and best judgement for any individual patient.

These statements have not been evaluated by the Food and Drug Administration. Ozzi is a dietary supplement and is not intended to diagnose, treat, cure, or prevent any disease. It is not a substitute for any medication or treatment prescribed by a healthcare professional. Nothing on this page is medical advice for any individual patient.

Questions, source documents, or corrections from clinicians: team@heyozzi.com

Version 1, 15 September 2026. Formula OZZI_CRAVE_V2. Customer-reported outcomes from the Ozzi customer survey, 29 June to 12 September 2026, n = 66.